Kiniksa Pharmaceuticals International (KNSA) Short-term Investments (2017 - 2026)

Kiniksa Pharmaceuticals International's Short-term Investments history runs 10 years deep, the most recent figure standing at $278.1 million for Q1 2026.

• Quarterly Short-term Investments rose 150.11% year-over-year to $278.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $278.1 million (up 150.11% YoY) and the FY2025 annual result came in at $248.5 million, up 313.81% from the prior year.
• Short-term Investments was $278.1 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $248.5 million in the prior quarter.
• Across five years, Short-term Investments topped out at $278.1 million in Q1 2026 and bottomed at $60.0 million in Q4 2024.
• A 5-year average of $125.5 million and a median of $111.2 million in 2025 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2024 — Short-term Investments tumbled 38.99% — and 2025, when it soared 313.81%.
• Kiniksa Pharmaceuticals International's Short-term Investments stood at $67.9 million in 2022, then jumped by 44.96% to $98.4 million in 2023, then slumped by 38.99% to $60.0 million in 2024, then surged by 313.81% to $248.5 million in 2025, then increased by 11.94% to $278.1 million in 2026.
• Business Quant data shows KNSA's Short-term Investments at $278.1 million in Q1 2026, $248.5 million in Q4 2025, and $177.2 million in Q3 2025.